Signal transduction of reactive oxygen species and mitogen-activated protein kinases in cardiovascular disease

Masanori Yoshizumi, Koichiro Tsuchiya, and Toshiaki Tamaki

Department of Pharmacology, The University of Tokushima School of Medicine, Tokushima, Japan

Abstract : Reactive oxygen species (ROS), generated by reduction-oxidation (redox) reactions, have been recognized as important chemical mediators that regulate signal transduction. It has been reported that increase in ROS generation may relate to a risk for cardiovascular diseases such as atherosclerosis, angina pectoris, and myocardial infarction. Therefore, understanding the ROS-generating biological processes and ROS-induced intracellular signaling will be informative to gain insights into the pathogenesis of these diseases. In this review, we focus on the sources and reactions of ROS in the cardiovascular system and the role of mitogen-activated protein (MAP) kinase pathway in redox-mediated signal transduction. Clinical implications of ROS and MAP kinase are then described to provide insight into the pathogenesis of various redox-sensitive cardiovascular diseases. The pathways responsible for ROS generation in the cardiovascular system may provide novel therapeutic targets. J. Med. Invest. 48 : 11-24, 2001

INTRODUCTION

Signal transduction is an event of conversion of signals from extracellular stimuli to intracellular responses that lead to change in gene expressions and cellular phenotypic modulations. Reactive oxygen species (ROS), generated by a variety of extracellular and intracellular mechanisms, have gained attention as novel signal mediators that regulate signal transduction events. Accumulating evidence suggests that ROS may be relevant to various cardiovascular diseases (1-3). In this review, we focused on the generation of ROS in cardiovascular systems and discussed ROS-mediated cell signaling, especially the role of mitogen-activated protein (MAP) kinases, in cardiovascular diseases.

ROS has been implicated as a major cause for the pathogenesis of myocardial ischemia and reperfusion injury (4, 5). ROS including hydrogen peroxide (H_2O_2), superoxide anion radical ($O_2^{\bullet-}$), hydroxyl radical ($^{\bullet}OH$), and peroxynitrite (ONOO) have been shown to increase upon reperfusion of the heart following ischemia (5-7). In ischemia and reperfused hearts, many alterations such as contractile dysfunction, arrhythmias, and changes in gene expression have been observed (8, 9). These alterations in the myocardium during ischemia-reperfusion were suggested to be, in part, due to oxidative stress. Clinically, antioxidants are believed to counteract with ROS and reduce the incidence of coronary artery disease (10). Intake of vitamin E decreased the incidence of cardiovascular events in the population of ischemic heart disease in the Cambridge Heart Antioxidant Study (CHAOS) (11). In addition, a multivitamins and probucol (MVP) trial revealed that an antioxidant, probucol was effective for prevention of restenosis after percutaneous transluminar coronary angioplasty (PTCA) procedure (12).

Based on the above studies, it is suggested that ROS may also be pathogenic for vascular diseases

such as atherosclerosis and restenosis. *In vivo* experiments revealed that the generation of $O_2^{\bullet-}$ increased in aortas from hyperlipidemic rabbits and coronary arteries from balloon-injured pigs compared with control vessels (13). It was also reported that administration of vitamins C and E decreased $O_2^{\bullet-}$ production from injured vessels (14). It is now apparent that change in the redox (reduction-oxidation) state is involved in the pathogenesis of various cardiovascular diseases.

SOURCES AND REACTIONS OF ROS

One of the major sources for ROS is mitochondria in cells. Mitochondrial respiration converts carbohydrates into high-energy metabolites such as adenosine triphosphate (ATP). This requires the sequential oxidation and reduction of the substrates using respiratory complexes. After oxidation by mitochondrial and plasma membrane oxidases, oxygen is reduced and the superoxide radical $O_2^{\bullet-}$ is formed (Fig. 1). Endoplasmic (sarcoplasmic) reticulum and nuclear membranes have also been shown to produce $O_2^{\bullet-}$ by a reaction of oxidative phosphorylation. The cell's endogenous defense system is dismutation of $O_2^{\bullet-}$ by superoxide dismutase (SOD) to produce hydrogen peroxide, H_2O_2. In biological systems, H_2O_2 is less reactive than $O_2^{\bullet-}$ and is metabolized by catalase or by peroxidase to form O_2 and H_2O (Fig. 1). Other important sources of ROS within cells are the metabolic by-products from biogenic cascade of

arachidonic acid by cyclooxygenase, lipoxygenase, and cytochrome p-450 monooxygenase. Xanthine oxidase and NADH/NADPH oxidase are also $O_2^{\bullet-}$ generating enzymes in cells. Xanthine oxidase is converted from xanthine dehydrogenase and mediates nucleotides metabolism, such as xanthine, to form $O_2^{\bullet-}$ and uric acid. NADH/NADPH oxidase is a multi-subunit enzyme that may be a major source of $O_2^{\bullet-}$ generation in the vasculature. The role of NADH/NADPH oxidase in vascular diseases will be discussed below. Two other ROS that would be important in vascular injury are hydroxyl radical ($^{\bullet}OH$) and peroxynitrite (ONOO⁻) (Fig. 1). In the presence of nitric oxide (NO), $O_2^{\bullet-}$ reacts more rapidly with NO than with SOD, to form ONOO⁻. ONOO⁻ readly reacts with tyrosine to form nitrotyrosine which may impair the vascular responses to stimuli. $^{\bullet}OH$ is a very reactive ROS that does not exist in large amounts under physiological conditions. However, under the presence of iron which may be released from red blood cells, $^{\bullet}OH$ would be generated via the Fenton reaction (or Haber-Weiss reaction) from H_2O_2.

ROS-MEDIATED MAP KINASE SIGNALING

ROS mediate activation of MAP kinases in a variety of cells leads to changes in gene expressions. MAP kinases are serine and threonine protein kinases that are activated by various extracellular stimuli and are encoded by a multigene family (Fig. 2) (15). MAP kinases are activated by phosphorylation on


Fig.1. Sources of reactive oxygen species (ROS) generated endogenously by cardiovascular cells and key metabolic pathways for these species. Multiple enzymes may induce ROS generation in cardiovascular cells, these include NADH/NADPH oxidase, xanthine oxidase, lipoxygenase, cyclooxygenase, p-450 monooxygenase, and the enzymes of mitochondrial oxidative phosphorylation. ($O_2^{\bullet-}$, superoxide anion radical ; H_2O_2, hydrogen peroxide ; $^{\bullet}OH$, hydroxyl radical ; ONOO⁻, peroxynitrite ; SOD, superoxide dismutase.) (Modified from Ref. 1 and 3 with permission.)

Threonine (T) and Tyrosine (Y) residues within a T-X-Y phosphorylation motif, where "X" can be Glu (E), Pro (P), or Gly (G). Three major classes of dual-specificity MAP kinases can be defined, based on their activation motifs (TEY, TPY, and TGY), which is termed ERK1/2 and BMK1 (also called ERK5), c-Jun N-terminal protein kinases (JNK, also called SAPK), and p38, respectively. Activation of the three classes of MAP kinases is charactreristic for particular stimuli. For example, growth factors and phorbol myristate acetate (PMA) activate ERK1/2 strongly, but JNK and p38 kinases, weakly (16). Hyperosmolar stress and TNF-α are strong stimuli for p38 (17). Berk *et al.* have shown that growth factors and angiotensin II are powerful activators of ERK1/2 in vascular smooth muscle cells (VSMC) (18). They also found that ROS activated ERK1/2

when the ROS was $O_2^{\bullet-}$ (19). In other systems, ROS activate JNK strongly (20). The specificity for MAP kinase activation is elucidated, in part, by members of the MAP kinase and ERK kinase (MEK) family that exhibit unique pairing with downstream MAP kinases. MEK1 and MEK2 activate ERK1/2, MKK3 and MKK6 activate p38, and SEK1 (MKK4) and MKK7 activate JNK. The specificity of activation of MAP kinases by individual stimuli is reiterated by specific substrates for each class (Fig. 2). Common substrates for the MAP kinases are transcription factors that, upon phosphorylation, induce changes in gene expression. ERK1/2 phosphorylates ternary complex factor (TCF)/Elk-1 on sites essential for transactivation (21). JNK phosphorylates c-Jun and increases its transcriptional activating potential (22). ATF2 is phosphorylated and activated by both JNK


Fig.2. Signal transduction pathways for mitogen-activated protein kinases (MAPKs) by oxidative stress in cardiovascular cells. Shown in a highly schematic linear pattern are modules of kinases that regulate each other in a kinase cascade. For example, oxidative stress is proposed to activate the small G protein Ras and thereby stimulate MAPK and ERK kinase (MEK) kinase (MEKK) and subsequent activation of MEK1, which is a regulator of the MAP kinase, ERK1/2. Additionally, it has been shown that other MAPKs including BMK1, JNK, and p38 may be regulated by oxidative stress. Among the targets for these MAP kinases are various transcription factors including Elk-1 (ternary complex factor, TCF), c-Jun, ATF-2, and CHOP. (Modified from Ref. 1 and 3 with permission)

ROLE OF MAP KINASES IN ISCHEMIA AND REPERFUSION INJURY IN THE HEART

There is growing evidence that multiple MAP kinases are activated during ischemia and/or reperfusion and may contribute to the structural and functional alterations after myocardial ischemia (2). Myocyte loss during the acute stage of myocardial infarction involves both apoptotic and necrotic cell death (26-28). Therefore, it is reasonable to conceive that the balance of cell survival and death is critical during the pathological evolution of postischemic cardiac dysfunction. Recent findings elucidated the possible role of MAP kinases in the balance of cell survival and death in ischemic myocardium. As shown in Fig. 3, Yu *et al.* revealed that three MAP kinase members (ERK1/2, JNK and p38) were activated in cardiomyocytes subjected to ischemia and reperfusion (29). They also showed that ERK1/2 is part of a survival pathway whereas JNK and p38 mediate the death pathway in the myocardium, based on experiments with their specific inhibitors. Among the substrates of ERK, p90 ribosomal S6 kinase (p90RSK) may mediate ERK-induced antiapoptotic signaling pathway. p90RSK is known to regulate gene expression via phosphorylation of transcription factors including c-Fos, cAMP-responsive element-binding protein (CREB) and to regulate protein synthesis by phosphorylation of polyribosomal proteins and glycogen synthese kinase-3. Recently, Bonni *et al.* (30) and Tan *et al.* (31) reported that p90RSK phosphorylated the proapoptotic protein BAD at serine 112, which specifically suppressed BAD-mediated apoptosis. These findings may imply that p90RSK and ERK promote cell survival by both inhibiting components of the cell death machinery (e.g. BAD) and increasing transcription of prosurvival genes (e.g. CREB). BMK1 has also been reported to be an antiapoptotic molecule from the findings of MEK5 inhibition, immediately upstream from BMK1 (25, 32). It was reported that BMK1 was activated in ischemia and reperfusion of the guinea pig heart (33). MEK5 and BMK1 are highly expressed in cardiomyocytes (33). MEK5-dependent BMK1 activation results in the phosphorylation of MEF2A and MEF2C, transcription factors that belong to the myocyte enhancer factor-2 (MEF-2) family (25), which are important regulators of cardiac gene expression.

It has been suggested that the pathways regulated by JNK and p38 contribute to apoptosis. The mecha-

Fig. 3.   Activation of ERK, JNK, and p38 in cardiomyocytes subjected to ischemia and reperfusion. Myocytes were exposed to ischemia or ischemia followed by reoxygenation for the indicated time period. Cells were harvested and extracted. Endogeneous MAPKs were immunoprecipitated, and the activities of ERK, JNK, and p38 were measured. Top, densitometric analysis of MAPKs activation. Bottom, representative autoradiogram. (Cited from Ref. 29 with permission.)

nisms by which JNK and p38-induced apoptosis are commonly cell and stimulus specific. For example, apoptosis induced by growth factor deprivation principally mediated through the activation of p38 rather than JNK (34). In some cells, JNK-mediated apoptosis has been shown to be involved in ubiquitination and degradation of p53, which may be regulated by JNK-mediated phosphorylation of p53 (35). However, p53 does not appear to be important for hypoxia-induced apoptosis in cardiomyocytes from the experiments using p53 knockout mice (36). Therefore, the mechanism of JNK-induced apoptosis remains unclear. The role of p38 in cardiomyocyte apoptosis is controversial because p38 can also induce cardiac hypertrophy. One reported way to explain the role of p38 in apoptosis is through its effect on cyclin D1 expression during cell cycle. It has been reported that the coexpression

of MKK3 along with p38 inhibits mitogen-induced cyclin D1 expression (37). However, contrasting findings have been reported that p38 phosphorylates MAPK-activated protein kinase 2 (MAPKAPK2), which in turn phosphorylates heat shock protein 27 (HSP27) and protects against apoptosis during ischemia (38). Activation of this pathway is cytoprotective and overexpression of HSP27 confers protection against ischemia in cardiomyocytes (39, 40). It was also reported that activation of p38 and JNK by anisomycin is cardioprotective (41). The controversies among studies may be explained by the existence of different p38 isoforms such as p38α which is proapoptotic whereas p38β may be antiapoptotic in neonate rat cardiomyocytes (42). The current evidence for JNK and p38 suggest multiple roles in ischemia and reperfusion, preconditioning, and hypertrophy of the heart. Further studies are needed to define the precise role of these MAP kinases in ischemia and reperfusion injury in the heart.

MAP KINASE-MEDIATED VASCULAR RE-MODELING REGULATED BY ROS

Vascular remodeling is a well described response of blood vessels to both physiologic and pathologic stimuli. It was originally defined by the findings that atherosclerotic vessels undergo a compensatory enlargement during atherosclerosis by the analysis of pathologic specimens (43). Recently, vascular remodeling was recognized to occur in animal models of ballon injury (13) and in patients after the PTCA procedure (44), and has been suggested to relate to restenosis. Several lines of evidence indicated that ROS and MAP kinases are involved in vascular remodeling under various pathological conditions. For example, we previously showed that exposure of vascular smooth muscle cells (VSMC) to H_2O_2 altered MAP kinase activity (Fig. 4) (45). In VSMC, ROS alters MAP kinase activity (19), protooncogene expression, and cell growth (46). Recently, it became clear that intracellular ROS generated by growth factors and cytokines may act as second messengers. Platelet-derived growth factor (PDGF) has been reported to increase intracellular ROS in VSMC (47). Increasing the intracellular levels of the scavenging enzyme catalase or the antioxidant glutathione prevented the PDGF-mediated increase in ROS. These ROS scavengers also blocked PDGF-induced tyrosine phosphorylation, ERK1/2 activation, DNA synthesis,

Fig. 4.   ERK, JNK, and p38 activation by hydrogen peroxide (H_2O_2) in vascular smooth muscle cells (VSMC). Time course (A, B) with 1 mM H_2O_2 and the concentration-response curve (C, D) (20 min for ERK1/2, 40 min for JNK, and 60 min for p38) are shown. Panels A and C are representative autoradiograms. Panels B and D are densitometric analysis of MAPKs activation. (Modified from Ref. 45.)

and chemotaxis, suggesting the role of ROS as second messengers. Activation of ERK1/2 has also been implicated in vascular endothelial growth factor (VEGF)-induced vascular endothelial cell (EC) survival (48). More recently, a general role for ROS in cell growth was suggested by the findings that v-Ras transformation was associated with increased ROS and that augmenting antioxidant defenses with catalase and SOD inhibited transformation and growth (49).

JNK and p38 are also sensitive to redox modulation (Fig. 4) (45). Members of the Rho family of small GTPases including Rac1 regulate these kinases (50). In contrast to ERK1/2, JNK and their downstream target c-Jun have been implicated in H_2O_2 and other stress-induced apoptosis of ECs (51). Moreover, p38 has been implicated in EC upregulation of intracellular adhesion molecule-1, and therefore, endothelial dysfunction (52). In VSMC, ROS mediated activation of p38 has also been implicated in cell migration (53).

Angiotensin II and endothelin are other activators of MAP kinases in VSMC and are believed to cause vascular remodeling (54, 55). Very recently, Griendling *et al*. showed that angiotensin II rapidly increased production of ROS via NADH/NADPH oxidase that reside in cell membranes (Fig. 5) (56). In blood vessels, a plasma membrane NADH/NADPH oxidase accounts for more than 90% of O_2^- formation (57). Interestingly, angiotensin II potently activates ERK1/2 and p38; however, only p38 is sensitive to both inhibition of NADH/NADPH oxidase activity and catalase overexpression in VSMC (58, 59). We obtained similar

findings that antioxidants preferentially inhibits JNK and p38 activation by angiotensin II but not ERK1/2 activation (unpublished observation). p22phox is a critical component of NADH/NADPH oxidase activity and transfection of antisense p22phox cDNA to VSMC inhibited angiotensin II-induced VSMC hypertrophy via a p38-dependent manner (60). It has also been reported that thrombin, TNF-α, and lactosylceramide also stimulate NADH/NADPH oxidase-dependent O_2^- generation in VSMC (61-63). In ECs, mechanical forces stimulate NADH/NADPH oxidase (64), but agonist responsiveness remains to be elucidated. Of note, NADH/NADPH oxidase is regulated at the protein level and may be increased by hormonal stimuli. For example, TNF-α increases NADH/NADPH oxidase activity in VSMC over 24 hours, an event that is dependent on increased transcription of p22phox (62). p22phox mRNA and O_2^- production are upregulated in the aortas of rats made hypertensive by angiotensin II infusion (65). It has become obvious that various vasoactive substances activate NADH/NADPH oxidase and produce ROS as second messengers in vascular cells. However, involvement of other sources of ROS, such as xanthine oxidase, lipoxygenese, and cyclooxygenase cannot be ruled out. It was recently reported that lipoxygenase metabolites of arachidonic acid mediate angiotensin II stimulation of the NADH/NADPH oxidase in VSMC (66). Further information concerning the activation mechanisms of the oxidase and protein targets of the oxidase-derived ROS should be clarified.

Fig.5. Structure and components of NADH/NADPH oxidase. Left side panel shows the scheme of the resting state of the components. Mitogenic oxidase-1 (mox-1) and p22phox form the electron transfer components of the oxidase, and p47phox and p67phox are cytosolic components that interact with these 2 proteins to modulate its activity. The small G protein Rac also serves a regulatory function. Right side panel shows the activated state of NADH/NADPH oxidase induced by agonists such as angiotensin II, endothelin, and PDGF etc.

OTHER SIGNALING MOLECULES ACTIVATED BY ROS

Although MAP kinases play a central role in ROS-mediated signal transduction in cardiovascular diseases, other signaling molecules also involved in ROS-mediated phenomena in cells. ROS participate in signal transduction by generating classic second-messengers (calcium and lipid mediators) that transmit the signal to intracellular mediators in both the cytoplasm and nucleus (Fig. 6).

Calcium-dependent signal transduction by ROS

ROS stimulate increases in calcium via at least three pathways. First, intracellular calcium release from endoplasmic (sarcoplasmic) reticulum occurs by generation of IP$_3$, which binds to an IP$_3$-sensitive calcium channel in endoplasmic (sarcoplasmic) reticulum. In addition, ROS may directly increase the open probability of calcium release channels. Previously, we reported that angiotensin II and endothelin, potent activators of NADH/NADPH oxidase as mentioned above, increased intracellular calcium in cardiomyocytes (67) and VSMC (68, 69). Moreover, a calcium-ATPase is required to maintain calcium

within the IP$_3$-sensitive pool, and inhibiting this ATPase would increase intracellular calcium (70). Secondly, in several cell types, ROS have been shown to stimulate extracellular calcium entry by effects on channels (71) and the sodium-calcium exchanger (72). Thirdly, mitochondria also store intracellular calcium, and significant oxidative stress inhibits this ability resulting in a release of calcium, especially in response to oxidized pyridine nucleotides (73, 74).

Phospholipid-dependent signal transduction by ROS

The finding that ROS increased intracellular calcium indicated that phospholipases were activated by ROS, because generation of IP$_3$ from PIP$_2$ is a well established mechanism in cardiovascular cells for the release of calcium from intracellular stores (75). At least three important phospholipases have been shown to be activated by ROS : phospholipase A$_2$ (PLA$_2$), phospholipase C (PLC), and phospholipase D (PLD). PLA$_2$ is likely activated by increases in intracellular calcium. It is important to note that many lipids generated by PLA$_2$ may themselves generate ROS through the action of monooxygenases. PLC is a calcium-dependent phospholipase that hydrolyses PIP$_2$ to generate IP$_3$ and diacylglycerol. Although there are no published


Fig.6. Redox regulation of signal transduction components. In addition to generation of intracellular O$_2^{\bullet-}$ by the enzymes, discussed in Fig. 1, extracellular stimuli including lipophilic substrates, membrane permeable oxidants (H$_2$O$_2$), cytokines and growth factors may modulate cellular redox state. The increased levels of reactive oxygen species (ROS) may act as second messengers to activate MAPKs, tyrosine kinases, and NF-κB, as well as inhibit protein tyrosine phosphatase (PTPase). As a consequence, there are alterations in the phosphorylation and activity of transcription factors, resulting in promotion of gene expression. (RTK, receptor tyrosine kinase ; PKC, protein kinase C) (Modified from Ref. 1 and 3 with permission.)

findings to suggest that ROS directly activate PLC, generation of ROS may be an early event in growth factor dependent signaling and activation of PLC. PLD has been shown to be stimulated by H_2O_2, fatty acid hydroperoxides (75, 76), and 4-hydroxynonenal in endothelial cells. Further studies are required to elucidate the mechanisms by which phospholipases are activated.

Tyrosine kinases as mediators of ROS-sensitive pathways

Tyrosine kinases are important as intracellular mediators because they are among the kinases most rapidly activated by many stimuli including ROS. Many growth factor receptors contain tyrosine kinase domains in their cytoplasmic portions (Fig. 6). Thus, a proximate signal event in growth factor signal transduction is receptor dimerization and activation of intrinsic tyrosine kinase. To date, there is no direct evidence that ROS stimulate receptor tyrosine kinases; however, three mechanisms have been proposed by which ROS activate tyrosine kinases. Firstly, tyrosine kinases may be activated by ROS directly by altering protein-protein interactions depending on sulfhydryl groups. Secondly, inhibition of phosphotyrosine phosphatases (PTPases) may be another important mechanism by which ROS activate tyrosine kinases. All PTPases contain a redox-sensitive cysteine at their active site (77), and oxidation of the sulfhydryl group inactivates the PTPase. Since many tyrosine kinases are inactivated by PTPases, oxidation of PTPases would stimulate tyrosine kinases. Thirdly, oxidation has been shown to stimulate proteolysis of regulatory proteins that may inhibit tyrosine kinase activation. Several tyrosine kinases are activated by ROS, among which Src family kinases have been described most frequently. p60Src, p56Lck, and p59Fyn of the Src family members have been found to be activated by H_2O_2 and other ROS. Two other ROS-sensitive tyrosine kinases identified in white blood cells are Syk and ZAP-70 (78). Of note, specific Src family kinases stimulate specific pathways leading to selective activation of MAP kinases. We previously found that c-Src mediates H_2O_2-induced JNK activation in VSMC (45). Abe *et al.* reported that BMK1 is activated via c-Src (58) whereas ERK1/2 is activated by Fyn (79). These findings indicate that c-Src and Fyn have separate role in ROS-mediated signal transduction. In addition, another tyrosine kinase Pyk2, a FAK related kinase, has been shown to be activated by ROS (80) and may activate other MAP kinases.

Small G proteins in ROS-sensitive signal transduction

Other important mediators of the ROS-sensitive signaling pathway are small G proteins. From the experiments with recombinant p21Ras *in vitro*, it was found that ROS directly promoted guanine nucleotide exchange on p21Ras (81). Furthermore, H_2O_2 activation of ERK2 was abolished by expression of dominant negative RasN-17 (49) or by treating with a farnesyltransferase inhibitor. Another small G protein, Rac may also regulate ROS production (Figs. 2, 6) (82). Expression of constitutively active V12-Rac1 in HeLa cells or stimulation with cytokine resulted in a significant increase in intracellular ROS. Treatment of cells with antioxidants inhibited the increase in ROS that occurred following V12-Rac1 expression. Potential mechanisms for small G protein activation include alterations of the lipid environment and inhibition of post-transcriptional modifications, such as palmitoylation, which may regulate small G protein activity.

ROS-induced activation of transcription factors: NF-κB and AP-1

Transcription factors are proteins that move to the nucleus upon activation and trigger gene expressions (Fig. 6). Nuclear factor-κB (NF-κB) is an inducible transcription activator that is a likely target for ROS signal transduction. NF-κB is a heterodimer containing a 50- and a 65-kD subunit (termed p50 and p65). There are two forms of NF-κB in the cell, an inactive form in the cytosol and an active form in the nucleus. Cytosolic NF-κB activation can be brought about by a variety of stimuli including cytokines, physical stress such as UV and ionizing radiation, and oxidants such as H_2O_2 (82-84). Activation of NF-κB by ROS may be pathogenic for atherosclerosis, as NF-κB can be activated in response to low-density lipoproteins (LDLs), an atherogenic diet, and advanced glycation end products (AGEs). In addition, recognition sequences for NF-κB are present in genes whose expression causes monocyte adhesion to endothelial cells and activation, such as E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intracellular adhesion molecule-1 (ICAM-1).

In addition to NF-κB, activator protein-1 (AP-1) appears to be activated by ROS (85). Regulation of AP-1 by ROS has been shown to involve ERK1/2 (86) and JNK (87) in a cell-and stimulus-specific manner. For example, metabolic oxidative stress in the liver increased AP-1 activity and stimulated binding of c-Fos, c-Jun, ATF-2, JunB, and JunD (87). ERK1/2 was shown to be necessary for phosphorylation of

the transcription factor Elk-1 and induction of the c-fos serum response element (86). In vascular smooth muscle, expression of mRNAs for c-fos and c-jun are rapidly induced by H_2O_2 and by arachidonic acid metabolites including 15-HETE and linoleic acid metabolites such as hydroperoxyoctadecadienoic acids (HPODEs) (88-90). Since these same stimuli also activate ERK1/2 in smooth muscle (19), it is likely that ERK1/2 play an important role in AP-1 activation. We also observed that endothelin-1 stimulates AP-1 activation probably through the activation of ERK1/2 in VSMC (55). Other transcription factors such as hypoxia-inducible factor-1 (HIF-1) and early growth response-1 (Egr-1) may be involved in ROS-mediated events and were described elsewhere (91, 92).

CLINICAL IMPLICATIONS OF ROS AND MAP KINASES IN CARDIOVASCULAR DISEASE

Although the role of MAP kinases in cardiac hypertrophy and apoptosis has been described in *in vivo* and in animal models, the role in human disease is not well documented. Recently, it was demonstrated that the expression of three MAP kinase members, ERK1/2, JNK, and p38 were confirmed in human heart (93). A potential clinical relevance for their action was reported by an increased activity of JNK and p38 in heart failure secondary to ischemic heart disease which may relate to ROS generation. It was also reported that activation of ERK1/2, JNK, and p38 was observed in human heart during coronary artery bypass grafting surgery (94). However, the clinical significance of MAP kinase activation in ischemia and heart failure of humans still remains to be elucidated. Gene transfer techniques provide insight into the role of MAP kinases in cardiac disease. In the gene transferred rat of dominant-negative SEK1, immediately upstream from JNK, cardiac hypertrophy was inhibited as evaluated by echocardiography and biochemical markers (95). In addition, an upstream regulator of p38, TAK1 was activated in cardiac hypertrophy of transgenic mice and TAK1 activation resulted in heart failure (96). These findings suggest the role of MAP kinases in cardiac disease, and therefore, MAP kinases are potential drug targets in the treatment of the disease.

Three vascular process in which ROS are likely to play a pathogenic role are hypertension, atherosclerosis, and vascular remodeling. Recently, it was shown that angiotensin II-induced hypertension was associated with increased vascular $O_2^{\bullet-}$ production and that

treatment with SOD reduced blood pressure by 50 mmHg in angiotensin II-infused rat (97). In addition, it was reported that the increase in MAP kinase activity was sustained in the angiotensin II-infused rat (98). These findings suggest that hypertension caused by chronically elevated angiotensin II and MAP kinase activity is mediated in part by $O_2^{\bullet-}$. Increases in ROS may affect the pathogenesis of atherosclerosis. Hypercholesterolemic animals and patients exhibit impaired endothelial dependent relaxation that can be restored with antioxidants (99). Clinically, it was also observed that vascular superoxide production by NADH/NADPH oxidase is associated with endothelial dysfunction in patients with hypercholesterolemia (100). ROS also cause oxidative modification of LDL, promoting uptake by the scavenger receptor and foam cell formation (101). These findings strongly suggest that the vascular redox state plays a pathogenic role in atherosclerosis. Vascular remodeling is also a ROS-sensitive phenomenon occuring clinically. It was reported that p22phox, a component of NADH/NADPH oxidase, expressed highly in the atherosclerotic remodeled specimens of the coronary artery (102). NADH/NADPH oxidase is a potent mediator of MAP kinase activation as mentioned above. Recent findings revealed that remodeling occurs in patients after the PTCA procedure (44) and remodeling is a key process for restenosis (103). The findings that antioxidants inhibit restenosis both *in vivo* (13) and clinically (12) may imply the role of ROS in vascular remodeling.

FUTURE DIRECTIONS

As discussed above, significant progress has been made in identifying and characterizing the sources of ROS and the role of MAP kinases in cardiovascular diseases. However, significant work should be performed to resolve the remaining issues. Firstly, additional information is required to clarify what molecule is really responsible for ROS generation in different cardiovascular cells including EC, VSMC, and cardiomyocytes. In addition, identification of the enzymatic and protein targets of ROS should be important. Of course, the ultimate goal is the development of new therapeutic strategies for the treatment of cardiovascular diseases of which ROS may be involved, in part, or in total. Understanding the molecular mechanisms of ROS generation and ROS-mediated alterations of signaling molecules including MAP kinases may provide insights into the pathogenesis of various cardiovascular diseases. Searching for ROS generating and ROS-mediated signaling molecules

is now ongoing in our labs and will inform help identify targets for the emerging therapeutic paradigm of gene therapy.

During the revision of this review, it has been reported that $G_{\alpha i}$ and $G_{\alpha o}$, subunits of heterotrimeric G protein, are potential targets of oxidative stress for activation of ERK (104).

ACKNOWLEDGMENTS

REFERENCES

1. Abe J, Berk BC : Reactive oxygen species as mediators of signal transduction in cardiovascular disease. Trends Cardiovasc Med 8 : 59-64, 1998

2. Abe J, Baines CP, Berk BC : Role of mitogen-activated protein kinases in ischemia and reperfusion-injury : the good and the bad. Circ Res 86 : 607-609, 2000

3. Berk BC : Redox signals that regulate the vascular response to injury. Thromb Haemostasis 82 : 810-817, 1999

4. Ferrari R, Ceconi C, Curello S, Guarnieri C, Caldarera CM, Albertini A, Visioli O : Oxygen-mediated myocardial damege during ischaemia and reperfusion : role of the cellular defences against oxygen toxicity. J Mol Cell Cardiol 17 : 937-945, 1985

5. Garlick PB, Davies MJ, Hearse DJ, Slater TF : Direct detection of free radicals in the reperfused rat heart using electron spin resonance spectroscopy. Circ Res 61 : 757-760, 1987

6. Grech ED, Dodd NJ, Jackson MJ, Morrison WL, Faragher EB, Ramsdale DR : Evidence for free radical generation after primary percutaneous transluminal coronary angioplasty recanalization in acute myocardial infarction. Am J Cardiol 77 : 122-127, 1996

7. Slezak J, Tribulova N, Pristacova J : Hydrogen peroxide changes in ischemic and reperfused heart. Cytochemistry and biochemical and X-ray microanalysis. Am J Pathol 147 : 772-781, 1995

8. Persad S, Panagia V, Dhalla NS : Role of H_2O_2 in changing beta-adrenoceptor and adenylyl cyclase in ischemia-reperfused hearts. Mol Cell Biochem 186 : 99-106, 1998

9. Temsah RM, Nitticadan T, Chapman D, Takeda S, Mochizuki S, Dhalla NS : Alterations in sarcoplasmic reticulum function and gene expression in ischemic-reperfused rat heart. Am J Physiol 277 : H584-H594, 1999

10. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC : Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 328 : 1450-1456, 1993

11. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ : Randomised controlled trial of vitamin E in patients with coronary disease : Cambridge Heart Antioxidant Study (CHAOS). Lancet 347 : 781-786, 1996

12. Tardif JC, Coté G, Lespérance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P : Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 337 : 365-372, 1997

13. Nunes GL, Sgoutas DS, Redden RA, Sigman SR, Gravanis MB, King III SB, Berk BC : Combination of vitamins C and E alters the response to coronary balloon injury in the pig. Arterioscler Thromb Vasc Biol 15 : 156-165, 1995

14. Nunes GL, Robinson K, Kalynych A, King III SB, Sgoutas DS, Berk BC : Vitamins C and E inhibit O_2^- production in the pig coronary artery. Circulation 96 : 3593-3601, 1997

15. Blenis J : Signal transduction via the MAP kinases : proceed at your own RSK. Proc Natl Acad Sci USA 90 : 5889-5892, 1993

16. Cano E, CA Hazzalin, and LC Mahadevan : Anisomycin-activated protein kinases p45 and p55 but not mitogen-activated protein kinases ERK-1 and -2 are implicated in the induction of c-fos and c-jun. Mol Cell Biol 14 : 7352-7362, 1994

17. Han J, Lee JD, Bibbs L, Ulevitch RJ : A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265 : 808-811, 1994

18. Duff JL, Berk BC, Corson MA : Angiotensin II stimulates the pp44 and pp42 mitogen-activated protein kinases in cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun 188 : 257-264, 1992

19. Baas AS, Berk BC : Differential activation of mitogen-activated protein kinases by H_2O_2 and O_2^- in vascular smooth muscle cells. Circ Res 77 : 29-36, 1995

20. Devary Y, Gottlieb RA, Smeal T, Karin M : The mammalian ultraviolet response is triggered by activation of src tyrosine kinases. Cell 71 : 1081-

1091, 1992

21. Marais R, Wynne J, Treisman R : The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 73: 381-393, 1993

22. Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J, Woodgett JR : The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369: 156-160, 1994

23. Gupta S, Campbell D, D'Erijard B, Davis RJ : Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267: 389-393, 1995

24. Raingeaud J, Gupta S, Rogers JS, Dickens M, Han J, Ulevitch RJ, Davis RJ : Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 270: 7420-7426, 1995

25. Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ, Lee JD : BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J 16: 7054-7066, 1997

26. Itoh G, Tamura J, Suzuki M, Suzuki Y, Ikeda H, Koike M, Nomura M, Jie T, Ito K : DNA fragmentation of human infarcted myocardial cells demonstrated by the nick end labeling method and DNA agarose gel electrophoresis. Am J Pathol 146: 1325-1331, 1995

27. Bardales RH, Hailey LS, Xie SS, Schaefer RF, Hsu SM : In situ apoptosis assay for the detection of early acute myocardial infarction. Am J Pathol 149: 821-829, 1996

28. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki LM : Apoptosis in human acute myocardial infarction. Circulation 95: 320-323, 1997

29. Yue T-L, Wang C, Gu J-L, Ma X-L, Kumar S, Lee JC, Feuerstein GZ, Thomas H, Maleeff B, Ohlstein EH : Inhibition of extracellular signal-regulated kinase enhances ischemia/reoxigenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart. Circ Res 86: 692-699, 2000

30. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME : Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and-independent mechanisms. Science 286: 1358-1362, 1999

31. Tan Y, Ruan H, Demeter MR, Comb MJ : p90 (RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. J Biol Chem

274: 34859-34867, 1999

32. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee JD : Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395: 713-716, 1998

33. Takeishi Y, Abe J, Lee JD, Kawakatsu H, Walsh RA, Berk BC : Differential regulation of p90 ribosomal S6 kinase and big mitogen-activated protein kinase 1 by ischemia/reperfusion and oxidative stress in perfused guinea pig hearts. Circ Res 85: 1164-1172, 1999

34. Kummer JL, Rao PK, Heidenreich KA : Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem 272: 20490-20494, 1997

35. Fuchs SY, Adler V, Pincus MR, Ronai Z : MEKK1/JNK signaling stabilizes and activates p 53. Proc Natl Acad Sci USA 95: 10541-10546, 1998

36. Webster KA, Discher DJ, Kaiser S, Hernandez O, Sato B, Bishopric NH : Hypoxia-activated apoptosis of cardiac myocytes requires reoxygenation or a pH shift and is independent of p53. J Clin Invest 104: 239-252, 1999

37. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J : Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 271: 20608-20616, 1996

38. Freshney NW, Rawlinson L, Guesdon F, Jones E, Cowley S, Hsuan J, Saklatvala J : Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 78: 1039-1049, 1994

39. Huot J, Houle F, Marceau F, Landry J : Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells. Circ Res 80: 383-392, 1997

40. Martin JL, Mestril R, Hilal-Dandan R, Brunton LL, Dillmann WH : Small heat shock proteins and protection against ischemic injury in cardiac myocytes. Circulation 96: 4343-4348, 1997

41. Nakano A, Baines CP, Kim SO, Pelech SL, Downey JM, Cohen MV, Critz SD : Ischemic preconditioning activates MAPKAPK2 in the isolated rabbit heart : evidence for involvement of p38 MAPK. Circ Res 86: 144-151, 2000

42. Wang Y, Huang S, Sah VP, Ross J Jr, Brown JH, Han J, Chien KR : Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family. J Biol Chem 273: 2161-2168, 1998

43. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ : Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316 : 1371-1375, 1987

44. Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Wong C, Hong MK, Kovach JA, Leon MB : Arterial remodeling after coronary angioplasty : a serial intravascular ultrasound study. Circulation 94 : 35-43, 1996

45. Yoshizumi M, Abe J, Haendeler J, Huang Q, Berk BC : Src and Cas mediate JNK activation but not ERK1/2 and p38 kinases by reactive oxygen species. J Biol Chem 275 : 11706-11712, 2000

46. Rao GN, Berk BC : Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 70: 593-599, 1992

47. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T : Requirement for generation of H_2O_2 for platelet-derived growth factor signal transduction. Science 270 : 296-299, 1995

48. Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P, Law PY, Hebbel RP : VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 247 : 495-504, 1999

49. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, Clermont-Goldschmidt PJ : Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275 : 1649-1652, 1997

50. Kyriakis JM, Avruch J : Sounding the alarm : protein kinase cascades activated by stress and inflammation. J Biol Chem 271 : 24313-24316, 1996

51. Wang N, Verna L, Hardy S, Zhu Y, Ma KS, Birrer MJ, Stemerman MB : c-Jun triggers apoptosis in human vascular endothelial cells. Circ Res 85 : 387-393, 1999

52. Tamura DY, Moore EE, Johnson JL, Zallen G, Aiboshi J, Silliman CC : p38 Mitogen-activated protein kinase inhibition attenuates intracellular adhesion molecule-1 up-regulation on human pulmonary microvascular endothelial cells. Surgery 124 : 403-407, 1998

53. Hedges JC, Dechert MA, Yamboliev IA, Martin JL, Hickey E, Weber LA, Gerthoffer WT : A role for p38 (MAPK)/HSP27 pathway in smooth muscle cell migration. J Biol Chem 274 : 24211-24219, 1999

54. Ishida M, Ishida T, Thomas S, Berk BC : Activation of extracellular signal-regulated kinases (ERK1/2) by angiotensin II is dependent on c-Src in vascular smooth muscle cells. Circ Res 82 : 7-12, 1998

55. Yoshizumi M, Kim S, Kagami S, Hamaguchi A, Tsuchiya K, Houchi H, Iwao H, Kido H, Tamaki T : Effect of endothelin-1 (1-31) on extracellular signal-regulated kinase and proliferation of human coronary artery smooth muscle cells. Brit J Pharmacol 125 : 1019-1027, 1998

56. Griendling KK, Sorescu D, Ushio-Fukai M : NAD(P)H oxidase : role in cardiovascular biology and disease. Circ Res 86 : 494-501, 2000

57. Mohazzab-H KM, Kaminski PM, Wolin MS : NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 266 : H2568-H2572, 1994

58. Abe J, Kusuhara M, Ulevitch RJ, Berk BC, Lee JD : Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase. J Biol Chem 271 : 16586-16590, 1996

59. Ushio-Fukai M, Alexander RW, Akers M, Griendling KK : p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem 273 : 15022-15029, 1998

60. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK : p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 271 : 23317-23321, 1996

61. Patterson C, Ruef J, Madamanchi NR, Barry-Lane P, Hu Z, Horaist C, Ballinger CA, Brasier AR, Bode C, Runge MS : Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin. Evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo. J Biol Chem 274 : 19814-19822, 1999

62. De Keulenaer GW, Alexander RW, Ushio-Fukai M, Ishizaka N, Griendling KK : Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J 329 : 653-657, 1998

63. Bhunia AK, Arai T, Bulkley G, Chatterjee S : Lactosylceramide mediates tumor necrosis factor-α-induced intracellular adhesion molecule-1 (ICAM-1) expression and the adhesion of neutrophil in human umbilical vein endothelial cells. J Biol Chem 273 : 34349-34357, 1998

64. De Keulenaer GW, Chappell DC, Ishizaka N, Nerem

RM, Alexander RW, Griendling KK : Oscillatory and steady laminar shear stress differentially affect human endothelial redox-state : role of a superoxide-producing NADH oxidase. Circ Res 82 : 1094-1101, 1998

65. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q, Taylor WR, Harrison DG, de Leon H, Wilcox JN, Griendling KK : p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80 : 45-51, 1997

66. Zafari AM, Ushio-Fukai M, Minieri CA, Akers M, Lasségue B, Griendling KK : Arachidonic acid metabolites mediate angiotensin II-induced NADH/NADPH oxidase activity and hypertrophy in vascular smooth muscle cells. Antioxidants & Redox Signaling 1 : 167-169, 1999

67. Fukuta Y, Yoshizumi M, Kitagawa T, Hori T, Katoh I, Houchi H, Tamaki T : Effect of angiotensin II on Ca^{2+} efflux from freshly isolated adult rat cardiomyocytes : possible involvement of Na^+/Ca^{2+} exchanger. Biochem Pharmacol 55 : 481-487, 1998

68. Yoshizumi M, Inui D, Okishima N, Houchi H, Tsuchiya K, Wakabayashi H, Kido H, Tamaki T : Endothelin-1-(1-31), a novel vasoactive peptide, increases $[Ca^{2+}]_i$ in human coronary artery smooth muscle cells. Eur J Pharmacol 348 : 305-309, 1998

69. Inui D, Yoshizumi M, Okishima N, Houchi H, Tsuchiya K, Kido H, Tamaki T : Mechanism of endothelin-1-(1-31)-induced calcium signaling in human coronary artery smooth muscle cells. Am J Physiol 276 : E1067-E1072, 1999

70. Sweetman LL, Zhang NY, Peterson H, Gopalakrishna R, Sevanian A : Effect of linoleic acid hydroperoxide on endothelial cell calcium homeostasis and phospholipid hydrolysis. Arch Biochem Biophys 323 : 97-107, 1995

71. Wang SY, Clague JR, Langer GA : Increase in calcium leak channel activity by metabolic inhibition or hydrogen peroxide in rat ventricular myocytes and its inhibition by polycation. J Mol Cell Cardiol 27 : 211-222, 1995

72. Reeves JP, Bailey CA, Hale CC : Redox modification of sodium-calcium exchange activity in cardiac sarcolemmal vesicles. J Biol Chem 261 : 4948-4955, 1986

73. Lehninger AL, Vercesi A, Bababunmi EA : Regulation of Ca^{2+} release from mitochondria by the oxidation-reduction state of pyridine nucleotides. Proc Natl Acad Sci USA 75 : 1690-1694, 1978

74. Sies H, Graf P, Estrela JM : Hepatic calcium efflux during cytochrome P-450-dependent drug oxidations at the endoplasmic reticulum in intact liver. Proc Natl Acad Sci USA 78 : 3358-3362, 1981

75. Itoh K, Yoshizumi M, Kitagawa T, Fukuta Y, Hori T, Houchi H, Tamaki T, Katoh I : Extracellularly administered lysophosphatidyl choline causes Ca^{2+} efflux from freshly isolated adult rat cardiomyocytes. Basic Res Cardiol 93 : 23-29, 1998

76. Natarajan V, Taher MM, Roehm B, Parinandi NL, Schmid HH, Kiss Z, Garcia JG : Activation of endothelial cell phospholipase D by hydrogen peroxide and fatty acid hydroperoxide. J Biol Chem 268 : 930-937, 1993

77. Brondello JM, McKenzie FR, Sun H, Tonks NK, Pouyss'egur J : Constitutive MAP kinase phosphatase (MKP-1) expression blocks G1 specific gene transcription and S-phase entry in fibroblasts. Oncogene 10 : 1895-1904, 1995

78. Schieven GL, Mittler RS, Nadler SG, Kirihara JM, Bolen JB, Kanner SB, Ledbetter JA : ZAP-70 tyrosine kinase, CD45, and T cell receptor involvement in UV-and H_2O_2-induced T cell signal transduction. J Biol Chem 269 : 20718-20726, 1994

79. Abe J, Okuda M, Huang Q, Yoshizumi M, Berk BC : Reactive oxygen species activate p90 ribosomal S6 kinase via fyn and ras. J Biol Chem 275 : 1739-1748, 2000

80. Matsuya M, Sasaki H, Aoto H, Mitaka T, Nagura K, Ohba T, Ishino M, Takahashi S, Suzuki R, Sasaki T : Cell adhesion kinase beta forms a complex with a new member, Hic-5, of proteins localized at focal adhesions. J Biol Chem 273 : 1003-1014, 1998

81. Lander HM, Ogiste JS, Teng KK, Novogrodsky A : p21ras as a common signaling target of reactive free radicals and cellular redox stress. J Biol Chem 270 : 21195-21198, 1995

82. Sulciner DJ, Irani K, Yu ZX, Ferrans VJ, Clermont-Goldschmidt P, Finkel T : rac1 regulates a cytokine-stimulated, redox-dependent pathway necessary for NF-κB activation. Mol Cell Biol 16 : 7115-7121, 1996

83. Bellas RE, Lee JS, Sonenshein GE : Expression of a constitutive NF-κB-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. J Clin Invest 96 : 7115-7121, 1995

84. Kranzhöfer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kübler W : Angiotensin induced inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 19 : 1623-1629, 1999

85. Schulze-Osthoff K, Los M, Baeuerle PA : Redox

signalling by transcription factors NF-κB and AP-1 in lymphocytes. Biochem Pharmacol 50: 735-741, 1995

86. Muller JM, Cahill MA, Rupec RA, Baeuerle PA, Nordheim A : Antioxidants as well as oxidants activate c-fos via Ras-dependent activation of extracellular-signal-regulated kinase 2 and Elk-1. Eur J Biochem 244 : 45-52, 1997

87. Mendelson KG, Contois LR, Tevosian SG, Davis RJ, Paulson KE : Independent regulation of JNK/p38 mitogen-activated protein kinases by metabolic oxidative stress in the liver. Proc Natl Acad Sci USA 93 : 12908-12913, 1996

88. Rao GN, Lasségue B, Griendling KK, Alexander RW, Berk BC : Hydrogen peroxide-induced c-fos expression is mediated by arachidonic acid release : role of protein kinase C. Nucl Acids Res 21 : 1259-1263, 1993

89. Rao GN, Baas AS, Glasgow WC, Eling TE, Runge MS, Alexander RW : Activation of mitogen-activated protein kinases by arachidonic acid and its metabolites in vascular smooth muscle cells. J Biol Chem 269 : 32586-32591, 1994

90. Rao GN, Alexander RW, Runge MS : Linoleic acid and its metabolites, hydroperoxyoctadecadienoic acids, stimulate c-Fos, c-Jun, and c-Myc mRNA expression, mitogen-activated protein kinase activation, and growth in rat aortic smooth muscle cells. J Clin Invest 96 : 842-847, 1995

91. Pages G, Milanini J, Richard DE, Berra E, Gothie E, Vinals F, Pouyssegur J : Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann NY Acad Sci 902 : 187-200, 2000

92. Yan SF, Lu J, Zou YS, Soh-Won J, Cohen DM, Buttrick PM, Cooper DR, Steinberg SF, Mackman N, Pinsky DJ, Stern DM : Hypoxia-associated induction of early growth response-1 gene expression. J Biol Chem 274 : 15030-15040, 1999

93. Cook SA, Sugden PH, Clerk A : Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischemic heart disease. J Mol Cell Cardiol 31 : 1429-1434, 1999

94. Talmor D, Applebaum A, Rudich A, Shapira Y, Tirosh A : Activation of mitogen-activated protein kinases in human heart during cardiopulmonary bypass. Circ Res 86 : 1004-1007, 2000

95. Choukroun G, Hajjar R, Fry S, del Monte F, Haq S, Guerrero JL, Picard M, Rosenzweig A, Force T : Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH₂-terminal kinases. J Clin Invest 104 : 391-398, 1999

96. Zhang D, Gaussin V, Taffet GE, Belaguli NS, Yamada M, Schwartz RJ, Michael LH, Overbeek PA, Schneider MD : TAK 1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat Med 6 : 556-563, 2000

97. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG : Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 95 : 588-593, 1997

98. Hamaguchi A, Kim S, Yano M, Yamanaka S, Iwao H : Activation of glomerular mitogen-activated protein kinases in angiotensin II-mediated hypertension. J Am Soc Nephrol 9 : 372-380, 1998

99. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P : The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332 : 488-493, 1995

100. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM : Vascular superoxide production by NAD(P)H oxidase : association with endothelial dysfunction and clinical risk factors. Circ Res 86 : E85-E90, 2000

101. Berliner JA, Heinecke JW : The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 20 : 707-727, 1996

102. Azumi H, Inoue N, Takeshita S, Rikitake Y, Kawashima S, Hayashi Y, Itoh H, Yokoyama M : Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation 100 : 1494-1498, 1999

103. Javier SP, Mintz GS, Popma JJ, Pichard AD, Kent KM, Satler LF, Leon MB : Intravascular ultrasound assessment of the magnitude and mechanism of coronary artery and lumen tapering. Am J Cardiol 75 : 177-180, 1995

104. Nishida M, Maruyama Y, Tanaka R, Kontani K, Nagao T, Kurose H : $G_{\alpha i}$ and $G_{\alpha o}$ are target proteins of reactive oxygen species. Nature 408 : 492-495, 2000